Cowen & Co upgrades King Pharmaceuticals (NYSE: KG) from Neutral to Outperform.

Cowen analyst says, "The FDA's Anesthetic and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE